These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

414 related items for PubMed ID: 22075489

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Proadrenomedullin, a useful tool for risk stratification in high Pneumonia Severity Index score community acquired pneumonia.
    Courtais C, Kuster N, Dupuy AM, Folschveiller M, Jreige R, Bargnoux AS, Guiot J, Lefebvre S, Cristol JP, Sebbane M.
    Am J Emerg Med; 2013 Jan; 31(1):215-21. PubMed ID: 23000327
    [Abstract] [Full Text] [Related]

  • 5. Prognostic value of proadrenomedullin in severe sepsis and septic shock patients with community-acquired pneumonia.
    Suberviola B, Castellanos-Ortega A, Llorca J, Ortiz F, Iglesias D, Prieto B.
    Swiss Med Wkly; 2012 Jan; 142():w13542. PubMed ID: 22430899
    [Abstract] [Full Text] [Related]

  • 6. Prognostic value of procalcitonin in community-acquired pneumonia.
    Schuetz P, Suter-Widmer I, Chaudri A, Christ-Crain M, Zimmerli W, Mueller B, Procalcitonin-Guided Antibiotic Therapy and Hospitalisation in Patients with Lower Respiratory Tract Infections (ProHOSP) Study Group.
    Eur Respir J; 2011 Feb; 37(2):384-92. PubMed ID: 20595156
    [Abstract] [Full Text] [Related]

  • 7. Usefulness of midregional proadrenomedullin to predict poor outcome in patients with community acquired pneumonia.
    Gordo-Remartínez S, Calderón-Moreno M, Fernández-Herranz J, Castuera-Gil A, Gallego-Alonso-Colmenares M, Puertas-López C, Nuevo-González JA, Sánchez-Sendín D, García-Gámiz M, Sevillano-Fernández JA, Álvarez-Sala LA, Andueza-Lillo JA, de Miguel-Yanes JM.
    PLoS One; 2015 Feb; 10(6):e0125212. PubMed ID: 26030588
    [Abstract] [Full Text] [Related]

  • 8. [Diagnostic and prognostic power of biomarkers to improve the management of community acquired pneumonia in the emergency department].
    Julián-Jiménez A, Timón Zapata J, Laserna Mendieta EJ, Sicilia-Bravo I, Palomo-de Los Reyes MJ, Cabezas-Martínez A, Laín-Terés N, Estebaran-Martín J, Lozano-Ancín A, Cuena-Boy R.
    Enferm Infecc Microbiol Clin; 2014 Apr; 32(4):225-35. PubMed ID: 24182623
    [Abstract] [Full Text] [Related]

  • 9. Red blood cell distribution width [RDW] and long-term mortality after community-acquired pneumonia. A comparison with proadrenomedullin.
    Bello S, Fandos S, Lasierra AB, Mincholé E, Panadero C, Simon AL, Gavin O, De Pablo F, Menendez R, Torres A.
    Respir Med; 2015 Sep; 109(9):1193-206. PubMed ID: 26205553
    [Abstract] [Full Text] [Related]

  • 10. Mid-regional proadrenomedullin: An early marker of response in critically ill patients with severe community-acquired pneumonia?
    Pereira JM, Azevedo A, Basílio C, Sousa-Dias C, Mergulhão P, Paiva JA.
    Rev Port Pneumol (2006); 2016 Sep; 22(6):308-314. PubMed ID: 27160747
    [Abstract] [Full Text] [Related]

  • 11. Predictive values of semi-quantitative procalcitonin test and common biomarkers for the clinical outcomes of community-acquired pneumonia.
    Ugajin M, Yamaki K, Hirasawa N, Yagi T.
    Respir Care; 2014 Apr; 59(4):564-73. PubMed ID: 24170911
    [Abstract] [Full Text] [Related]

  • 12. Performance of pro-adrenomedullin for identifying adverse outcomes in community-acquired pneumonia.
    España PP, Capelastegui A, Mar C, Bilbao A, Quintana JM, Diez R, Esteban C, Bereciartua E, Unanue U, Uranga A.
    J Infect; 2015 May; 70(5):457-66. PubMed ID: 25499199
    [Abstract] [Full Text] [Related]

  • 13. Usefulness of procalcitonin levels in community-acquired pneumonia according to the patients outcome research team pneumonia severity index.
    Masiá M, Gutiérrez F, Shum C, Padilla S, Navarro JC, Flores E, Hernández I.
    Chest; 2005 Oct; 128(4):2223-9. PubMed ID: 16236878
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Blood biomarkers for personalized treatment and patient management decisions in community-acquired pneumonia.
    Schuetz P, Litke A, Albrich WC, Mueller B.
    Curr Opin Infect Dis; 2013 Apr; 26(2):159-67. PubMed ID: 23434895
    [Abstract] [Full Text] [Related]

  • 18. Prognostic performance of MR-pro-adrenomedullin in patients with community acquired pneumonia in the Emergency Department compared to clinical severity scores PSI and CURB.
    Legramante JM, Mastropasqua M, Susi B, Porzio O, Mazza M, Miranda Agrippino G, D Agostini C, Brandi A, Giovagnoli G, Di Lecce VN, Bernardini S, Minieri M.
    PLoS One; 2017 Apr; 12(11):e0187702. PubMed ID: 29161297
    [Abstract] [Full Text] [Related]

  • 19. Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia.
    Menéndez R, Martínez R, Reyes S, Mensa J, Filella X, Marcos MA, Martínez A, Esquinas C, Ramirez P, Torres A.
    Thorax; 2009 Jul; 64(7):587-91. PubMed ID: 19131448
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.